Following on from information provided to NICE by the company in May 2019, the appraisal of Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1562 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2019, the appraisal of Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 July 2019 | Suspended. The company have informed NICE that the CM-498 clinical trial did not reach its primary endpoint. The company will not be applying for a marketing authorisation for this indication at this time. This appraisal is therefore suspended. |
| 21 February 2019 - 21 March 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 24 April 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual